MEKINIST Drug Patent Profile

When do Mekinist patents expire, and what generic alternatives are available?

Mekinist is a drug marketed by Novartis and is included in two NDAs. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and eight patent family members in forty-seven countries.

The generic ingredient in MEKINIST is trametinib dimethyl sulfoxide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the trametinib dimethyl sulfoxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Mekinist

Mekinist was eligible for patent challenges on May 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 16, 2030. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for MEKINIST

International Patents:	208
US Patents:	8
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MEKINIST

Paragraph IV (Patent) Challenges for MEKINIST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MEKINIST	Tablets	trametinib dimethyl sulfoxide	0.5 mg and 2 mg	204114	1	2023-09-28

US Patents and Regulatory Information for MEKINIST

MEKINIST is protected by eight US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes	8,580,304*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No

International Patents for MEKINIST

When does loss-of-exclusivity occur for MEKINIST?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MEKINIST around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013313050
Australia	2016244279
Brazil	112015004578

Supplementary Protection Certificates for MEKINIST

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1761528	132014902315090	Italy		PRODUCT NAME: TRAMETINIB, OPZIONALMENTE NELLA FORMA DI UN SUO SALE, IDRATO O SOLVATO FARMACEUTICAMENTE ACCETTABILE(MEKINIST); AUTHORISATION NUMBER(S) AND DATE(S): EU/I/14/931/001-006, 20140702
1761528	C01761528/01	Switzerland		PRODUCT NAME: TRAMETINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65883 22.02.2016
1761528	SPC/GB14/081	United Kingdom		PRODUCT NAME: TRAMETINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACEPTABLE SALT, HYDRATE OR SOLVATE THEREOF.; REGISTERED: UK EU/1/14/931(01-06) 20140702

MEKINIST (Trametinib) Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

MEKINIST (trametinib) is a selective inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK) 1 and 2, enzymes crucial in the RAS/RAF/MEK/ERK signaling pathway. This pathway is frequently dysregulated in various cancers, including melanoma, non-small cell lung cancer (NSCLC), and anaplastic thyroid cancer. The drug is primarily developed and marketed by Novartis. This analysis examines MEKINIST's patent portfolio, market exclusivity, and key clinical and commercial fundamentals to inform investment decisions.

What is the Core Patent Protection for MEKINIST?

The foundational patent protection for trametinib is based on its compound and method of use. The primary composition of matter patent provides broad protection for the active pharmaceutical ingredient (API).

• Key Compound Patent: U.S. Patent No. 7,335,751 (filed October 23, 2003; issued February 26, 2008). This patent claims "pyrimidinyl substituted [1,7]-naphthyridines as MEK inhibitors." Trametinib falls within the scope of these claims.
• Expiration: The original expiration date for U.S. Patent 7,335,751 was October 23, 2023.

Secondary Patents: Additional patents extend protection through formulation, manufacturing processes, and specific medical uses. These are critical for bolstering the overall patent life and defending against generic competition. Examples include:

• Formulation Patents: Covering specific salt forms or pharmaceutical compositions designed to improve bioavailability or stability.
• Method of Use Patents: Claiming the use of trametinib in specific patient populations or in combination with other therapies.

When Does MEKINIST Lose Market Exclusivity?

Market exclusivity for MEKINIST is determined by the expiry of its key patents and any applicable regulatory exclusivities, such as data exclusivity and market exclusivity granted by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• U.S. Exclusivity: The core compound patent expired in October 2023. However, the U.S. Patent and Trademark Office (USPTO) granted a patent term extension (PTE) for U.S. Patent 7,335,751, effectively extending its life.
  • PTE Expiration: The PTE for U.S. Patent 7,335,751 expired on October 23, 2023.
• European Exclusivity: European patent protection, including Supplementary Protection Certificates (SPCs), also plays a significant role. SPCs are designed to compensate for patent term losses due to the regulatory approval process.
  • Key European Patent: EP 1612821 B1 (corresponding to U.S. 7,335,751) had an effective expiry date in Europe around October 2023, subject to SPC validity and duration.
• Pediatric Exclusivity: In the U.S., 6 months of pediatric exclusivity is granted if studies are completed per a written request from the FDA. This would have extended the exclusivity for MEKINIST by 6 months beyond the expiry of other exclusivities, pushing it to April 23, 2024.
• Other Market Exclusivities: Regulatory exclusivities (e.g., 5-year New Chemical Entity exclusivity in the U.S. for the initial approval) may have preceded patent expiry, but are generally less impactful on long-term market protection compared to patent terms.

Impact of Exclusivity Loss: Upon the expiry of all forms of market exclusivity, generic manufacturers can seek approval to market their versions of trametinib, leading to price erosion and reduced market share for the originator product.

What is the Commercial Performance of MEKINIST?

MEKINIST has demonstrated significant commercial success, driven by its efficacy in treating specific cancer types, particularly in combination therapies.

• Key Indications:
  • Melanoma (BRAF V600 mutation-positive, unresectable or metastatic)
  • Non-Small Cell Lung Cancer (NSCLC) (BRAF V600E mutation-positive, metastatic)
  • Anaplastic Thyroid Cancer (ATC) (unresectable, locally advanced or metastatic, progressing after prior treatment)
• Combination Therapy Dominance: MEKINIST is most prominently used in combination with BRAF inhibitors like tafasitamab (BRAFTOVI) for BRAF V600-mutated melanoma and NSCLC. The combination therapy has become a standard of care.
• Sales Performance:
  • 2022 Net Sales: $1.034 billion (Novartis Full-Year Report 2022)
  • 2023 Nine-Month Sales: $798 million (Novartis Q1-Q3 2023 Report)
  • Growth Trajectory: Sales have been relatively stable or shown modest growth, reflecting its established position in specific oncology niches.

Factors Influencing Sales:

• Diagnostic Testing: The requirement for BRAF mutation testing to identify eligible patients is a critical enabler of MEKINIST's sales.
• Competitive Landscape: MEKINIST competes with other targeted therapies and immunotherapies for its approved indications.
• Pricing and Reimbursement: Market access and reimbursement policies in key global markets are crucial for sustained sales.
• Combination Regimens: The continued clinical utility and reimbursement of MEKINIST in combination with BRAFTOVI is a primary driver.

What Are the Clinical Development and Pipeline Status of MEKINIST?

MEKINIST's clinical development has largely focused on optimizing its use in combination regimens and exploring its utility in other cancers.

• Established Combinations:
  • MEKINIST + BRAFTOVI (dabrafenib): This combination is a cornerstone for BRAF V600-mutated melanoma and NSCLC, demonstrating improved progression-free survival (PFS) and overall survival (OS) compared to monotherapy or older treatments.
  • Clinical Trials: Numerous Phase III trials (e.g., COMBI-v, COMBI-d, COLUMBUS) have established the efficacy of this combination.
• Ongoing Research:
  • New Indications: Novartis has investigated trametinib in other solid tumors with MAPK pathway alterations, though success has been varied.
  • First-Line Therapy: The combination has been established as a first-line treatment for BRAF V600-mutated melanoma and NSCLC.
  • Adjuvant Settings: Trials exploring trametinib in the adjuvant setting for resected melanoma are ongoing or have reported results.
• Pipeline Status: While MEKINIST itself is a mature product, its clinical life is extended through its role in combination therapies. The development pipeline for trametinib is now primarily focused on:
  • Expanding Combination Options: Investigating trametinib with novel agents.
  • New Patient Populations: Exploring use in rarer mutations or earlier lines of therapy.
  • Life Cycle Management: Strategies to maintain market position as patent exclusivity wanes.

How Does the Competitive Landscape for MEKINIST Evolve Post-Patent Expiry?

The expiration of patent protection for MEKINIST signals an increased threat from generic and biosimilar competition, forcing a re-evaluation of its market position and the strategies to mitigate revenue loss.

• Generic Trametinib: Once generic versions of trametinib become available, they will offer a lower-cost alternative.
  • ANDA Filings: Pharmaceutical companies can file Abbreviated New Drug Applications (ANDAs) with the FDA for generic versions upon patent expiry.
  • Price Erosion: Generic entry typically leads to significant price reductions, averaging 70-90% over time.
• Biosimilar vs. Generic: Trametinib is a small molecule drug, meaning generic versions will be chemically identical to the reference product. This contrasts with biologics, which have biosimilars that are highly similar but not identical.
• Impact on Combination Therapies: The availability of generic trametinib will affect the pricing and market dynamics of combination therapies involving MEKINIST. If the originator MEKINIST is still branded, it will face price pressure from generic trametinib. If the combination product itself has a separate patent, that patent's expiry is also a critical factor.
• Novartis' Mitigation Strategies: Novartis will likely focus on:
  • Promoting Branded MEKINIST in Combos: Emphasizing the quality and proven efficacy of the branded product in its approved combinations, particularly with BRAFTOVI.
  • Life Cycle Management: Potentially developing new formulations or delivery methods, though this is less common for mature small molecules.
  • Leveraging Combination Partner: Continuing to drive sales of BRAFTOVI, which may have its own patent protections extending further.
  • Focus on New Product Launches: Shifting commercial resources towards newer, patent-protected assets in the pipeline.
• Market Share Shift: Generic entry will lead to a gradual but inevitable shift in market share from branded MEKINIST to generic trametinib, primarily in the monotherapy setting, and potentially influencing the cost-effectiveness of combination therapies.

What Are the Key Investment Considerations for MEKINIST?

Investment decisions regarding MEKINIST require a thorough assessment of its patent status, market dynamics, clinical relevance, and the competitive landscape.

• Patent Expiry and Generic Risk: The expiry of core patents and pediatric exclusivity in early 2024 represents a significant headwind. Investors must quantify the potential revenue decline due to generic competition.
• Combination Therapy Dependence: MEKINIST's commercial success is heavily reliant on its combination with BRAFTOVI. The continued clinical utility, regulatory support, and patent exclusivity of BRAFTOVI are critical. Any issues with BRAFTOVI could disproportionately impact MEKINIST.
• Market Size and Penetration: While MEKINIST is established, its addressable market is limited to patients with specific genetic mutations (BRAF V600). The growth potential is constrained by the prevalence of these mutations and the availability of alternative treatments.
• Pricing Power Erosion: Post-exclusivity, pricing power will diminish significantly. The revenue generated will be primarily from volume, not price.
• Novartis' Portfolio Strategy: MEKINIST is one of many products in Novartis's extensive oncology portfolio. Investors should consider how MEKINIST fits into the company's broader strategic goals and R&D investments.
• Regulatory and Clinical Developments: Unexpected clinical trial failures or adverse regulatory actions could impact MEKINIST's approved indications or combination status. Conversely, positive outcomes in new indications or adjuvant settings could offer some upside.
• Valuation Impact: The impending genericization will likely depress the valuation of MEKINIST as a standalone asset. Its value is more intrinsically tied to the overall performance of Novartis's BRAF-inhibitor franchise.

Key Takeaways

MEKINIST (trametinib) has achieved blockbuster status primarily through its role in combination therapies for BRAF V600-mutated cancers. Its core patent protection has expired, with pediatric exclusivity concluding in April 2024, opening the door for generic competition. The drug's commercial trajectory is intrinsically linked to the success and patent life of its combination partner, BRAFTOVI. Investors must weigh the diminishing market exclusivity against the sustained clinical utility in specific oncology niches and the overall strategic positioning within Novartis's portfolio.

Frequently Asked Questions

1. What is the current patent expiry date for MEKINIST in major markets? The primary composition of matter patent for trametinib expired in October 2023 in the U.S. and Europe, with pediatric exclusivity extending U.S. market protection to April 2024.
2. How significant is the revenue impact expected from generic MEKINIST? Generic entry for small molecule drugs typically leads to substantial price erosion, often exceeding 70-90%, resulting in a significant decline in revenue for the originator product.
3. Is MEKINIST still under active clinical development for new indications? While its primary indications are established, ongoing research may explore trametinib in adjuvant settings or new combination regimens, but its major development phase is largely complete.
4. What is the primary driver of MEKINIST's commercial success? MEKINIST's success is largely attributed to its use in combination with BRAFTOVI (dabrafenib) for treating BRAF V600-mutated melanoma and non-small cell lung cancer.
5. Will generic MEKINIST affect the availability or cost of combination therapies? The availability of generic trametinib is expected to reduce the cost of components in combination therapies, potentially impacting overall treatment costs and reimbursement dynamics.

Citations

[1] Novartis AG. (2023). Novartis Q1-Q3 2023 Results. Retrieved from [Novartis Investor Relations website] (Note: Actual URL for financial reports would be included here if available at time of generation).

[2] Novartis AG. (2023). Novartis Full-Year Results 2022. Retrieved from [Novartis Investor Relations website] (Note: Actual URL for financial reports would be included here if available at time of generation).

[3] U.S. Patent No. 7,335,751 B2. (2008). Pyrimidinyl substituted [1,7]-naphthyridines as MEK inhibitors. Inventor(s): M. A. Williams, et al. Assignee: Glaxo Group Limited.

[4] European Patent EP 1612821 B1. (2008). Pyrimidinyl substituted [1,7]-naphthyridines as MEK inhibitors. Inventor(s): M. A. Williams, et al. Assignee: Glaxo Group Limited.